Physician profile
Daniel N Amponsah
NPI 1093997579
$1,646.07
in general payments reported to CMS, 2019-2025
9 companies · $70.71 in 2025
The $70.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $69.60 · 2021: $72.84 · 2022: $72.51 · 2023: $89.81 · 2024: $892 · 2025: $70.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.35 |
| Education | $239.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $487.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.50 | 2024 | Jardiance |
| Abbott Laboratories | $295.70 | 2023-2024 | Ensite, Tacticath |
| Genentech USA, INC. | $125.14 | 2019 | |
| Allergan, INC. | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.26 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $44.90 | 2024-2025 | Dificid, Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $40.97 | 2022-2023 | Eliquis |
| Stryker Corporation | $21.46 | 2025 | Clottriever Bold Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Amponsah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.